The Pharmacy Times® Immuno-oncology Resource Center is a comprehensive resource for clinical news and expert insights on treatments that harness the body's immune system to fight cancer.
July 14th 2024
Treatment of advanced/metastatic urothelial cancer has changed dramatically in recent years. This review discusses the use, risks, and benefits of several novel therapies for this indication.
Improving the Delivery of CAR T-Cell Therapy for Multiple Myeloma
1.0 Credit / Oncology
View More
The Challenges of Chemotherapy Drug Shortages: The Oncology Pharmacist’s Perspective and Opportunities for Mit...
1.0 Credit / Oncology
View More
Preparing for the Use of Multi-Cancer Early Detection Tests: Opportunities for Managed Care Professionals to E...
1.5 Credits / Oncology
View More
Optimizing Safety and Utilization of Targeted Therapies in MET- or RET-Altered Non-Small Cell Lung Cancer
1.0 Credit / Oncology
View More
Non-Melanoma Skin Cancers: The Evolution of Treatment With Immune Checkpoint Inhibitors and Its Implications f...
1.0 Credit / Oncology, Dermatology
View More
Assessing Emerging Therapies and Multidisciplinary Practices in Managing Myelofibrosis
1.5 Credits / Hematology, Oncology
View More
Navigating the Complexities of Oncologic Immunotherapy and Vascular Endothelial Growth Factor Receptor Tyrosin...
1.5 Credit / Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Revolutionizing the Treatment of Endometrial Cancer by Leveraging the Potential of Immune Checkpoint Inhibitor...
1.0 Credits / Oncology
View More
Balancing the Benefits and Risks of Asparaginase Treatment in Adults and Young Adults With Acute Lymphoblastic...
1.0 Credits / Oncology
View More
Maximizing Efficacy and Minimizing Toxicity of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
1.0 Credits / Oncology
View More
PARP Inhibitors for Ovarian Cancer: An Oncology Pharmacist's Guide to the Latest Clinical Advancements
1.0 Credits / Oncology
View More
Emerging Trends in the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma Treatment
1.0 Credits / Oncology
View More
Recognizing the Signs and Symptoms of Cytokine Release Syndrome in Novel Cancer Therapies: Strategies for Onco...
1.0 Credits / Oncology
View More
Balancing Anticancer Efficacy and Cardiovascular Safety: A Pharmacist's Guide
1.0 Credits / Oncology
View More
Optimizing Use of Small Molecule Inhibitors in Chronic Lymphocytic Leukemia: Strategies for Safe and Effective...
1.0 Credits / Hematology, Oncology
View More
Navigating the Evolving Treatment Landscape of Metastatic Renal Cell Carcinoma
2.0 Credits / Nephrology, Oncology
View More
Advances in the Treatment of Metastatic Renal Cell Carcinoma: New Horizons in Targeted Therapies
1.0 Credit / Genitourinary Cancer, Oncology
View More
Optimizing Asparaginase Use in Acute Lymphoblastic Leukemia: A Comprehensive Program on Safety and Efficacy
1.0 Credit / Genitourinary Cancer, Oncology
View More
Navigating Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatment: An Interdisciplinary Approach
1.5 Credits / Oncology
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung C...
1.5 Credits / Lung Cancer, Oncology
View More
Navigating the Evolving Landscape of HER2-Positive Early-Stage Breast Cancer: Considerations for Managed Care
2.0 Credits / Breast Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strateg...
1.0 Credit / Oncology, Hematologic Cancer
View More
Managed Care Approaches to Improve Outcomes in Frontline Therapy for Renal Cell Carcinoma
2.0 Credits / Oncology
View More
Desmoid Tumors: What Managed Care Professionals Need to Know to Manage These Unpredictable Tumors, featuring a...
2.0 Credits / Oncology
View More
Challenges in Treatment of Desmoid Tumors and Managed Care Solutions
0.5 Credit / Oncology
View More
Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization
1.0 Credit / Breast Cancer, Women’s Health, Oncology
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
FDA Approves Pembrolizumab Resectable Non–Small Cell Lung Cancer
October 17th 2023Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.
Read More
Enfortumab Vedotin-ejfv, Pembrolizumab Combination Shows Promise Treating Urothelial Cancer
September 26th 2023Investigators reported that enfortumab vedotin-ejfv (Padcev; Astella Pharma Inc, Seagen Inc) in combination with pembrolizumab (Keytruda; Merck & Co Inc) met the dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer.
Read More
Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma
September 22nd 2023Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.
Read More
Study Suggests Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia Treatment
September 14th 2023The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.
Read More
Liso-Cel Produces Deep, Durable Responses in Patients with Hard-to-Treat Lymphomas
June 22nd 2023Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Read More
Axi-Cel Use in Patients With Large B-Cell Lymphoma Leads to Longer Overall Survival
June 16th 2023A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.
Read More